Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014-2019: a retrospective cohort study.
Journal
Pneumonia (Nathan Qld.)
ISSN: 2200-6133
Titre abrégé: Pneumonia (Nathan)
Pays: England
ID NLM: 101663459
Informations de publication
Date de publication:
25 Mar 2023
25 Mar 2023
Historique:
received:
13
10
2022
accepted:
05
01
2023
entrez:
25
3
2023
pubmed:
26
3
2023
medline:
26
3
2023
Statut:
epublish
Résumé
Since the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children < 16 years old in Germany from 2014-2019. A nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged < 16 years were identified using ICD-10-GM codes. HCRU was estimated from annual rates of outpatient visits, outpatient antibiotic prescriptions and inpatient admissions, divided by person-years (PY) at-risk. Average direct medical costs per episode were estimated as the total cost of all HCRU, divided by the total number of episodes. The Mann-Kendall test was used to assess monotonic time trends from 2014-2019. During 2014-2019, 916,805 children aged < 16 years were followed up for a total of 3,608,716 PY. The average costs per episode for out-versus inpatient care associated with PP and ACP were €67 (95% CI 58-76) versus €2,606 (95% CI 1,338-3,873), and €63 (95% CI 62-63) versus €620 (95% CI 598-641), respectively. For IPD, the average medical cost per episode for out-versus inpatients were €30 (95% CI 19-42) versus €6,051 (95% CI 3,323-8,779), respectively. There were no significant trends in HCRU or costs for IPD or pneumonia over the study period, except for a significant reduction in ACP outpatient visits. A significant decrease in rate of outpatient visits and antibiotic prescribing for recurrent AOM was observed, in addition to an increase in rates of hospital admissions for simple AOM. This was paralleled by a significant increase in inpatient costs per episode for treating AOM overall, and simple AOM, over the study period. The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014-2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.
Sections du résumé
BACKGROUND
BACKGROUND
Since the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children < 16 years old in Germany from 2014-2019.
METHODS
METHODS
A nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged < 16 years were identified using ICD-10-GM codes. HCRU was estimated from annual rates of outpatient visits, outpatient antibiotic prescriptions and inpatient admissions, divided by person-years (PY) at-risk. Average direct medical costs per episode were estimated as the total cost of all HCRU, divided by the total number of episodes. The Mann-Kendall test was used to assess monotonic time trends from 2014-2019.
RESULTS
RESULTS
During 2014-2019, 916,805 children aged < 16 years were followed up for a total of 3,608,716 PY. The average costs per episode for out-versus inpatient care associated with PP and ACP were €67 (95% CI 58-76) versus €2,606 (95% CI 1,338-3,873), and €63 (95% CI 62-63) versus €620 (95% CI 598-641), respectively. For IPD, the average medical cost per episode for out-versus inpatients were €30 (95% CI 19-42) versus €6,051 (95% CI 3,323-8,779), respectively. There were no significant trends in HCRU or costs for IPD or pneumonia over the study period, except for a significant reduction in ACP outpatient visits. A significant decrease in rate of outpatient visits and antibiotic prescribing for recurrent AOM was observed, in addition to an increase in rates of hospital admissions for simple AOM. This was paralleled by a significant increase in inpatient costs per episode for treating AOM overall, and simple AOM, over the study period.
CONCLUSIONS
CONCLUSIONS
The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014-2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.
Identifiants
pubmed: 36964592
doi: 10.1186/s41479-023-00105-9
pii: 10.1186/s41479-023-00105-9
pmc: PMC10039501
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7Informations de copyright
© 2023. Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
Références
Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):638-41
pubmed: 19620582
Vaccine. 2018 Nov 26;36(49):7479-7486
pubmed: 30385056
BMC Pediatr. 2022 Apr 13;22(1):204
pubmed: 35418046
Bull World Health Organ. 2004 Dec;82(12):895-903
pubmed: 15654403
PLoS One. 2017 May 9;12(5):e0177113
pubmed: 28486544
JAMA. 2009 Aug 19;302(7):758-66
pubmed: 19690308
Wkly Epidemiol Rec. 2012 Apr 6;87(14):129-44
pubmed: 24340399
Acad Emerg Med. 2007 Jul;14(7):646-52
pubmed: 17554009
Cochrane Database Syst Rev. 2014 Apr 02;(4):CD001480
pubmed: 24696098
Eur J Health Econ. 2017 Apr;18(3):273-292
pubmed: 26905404
Lancet Glob Health. 2019 Jan;7(1):e58-e67
pubmed: 30554762
Pediatr Infect Dis J. 2014 May;33(5):453-7
pubmed: 24732389
BMC Infect Dis. 2015 Oct 14;15:419
pubmed: 26468008
Ear Nose Throat J. 2021 Jun;100(3_suppl):325S-332S
pubmed: 32579395
Value Health. 2019 Nov;22(11):1329-1344
pubmed: 31708071
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
Curr Otorhinolaryngol Rep. 2017;5(2):115-124
pubmed: 28616365
Lancet Infect Dis. 2018 Apr;18(4):441-451
pubmed: 29395999
BMC Infect Dis. 2019 Jun 10;19(1):510
pubmed: 31182036
JAMA Pediatr. 2014 Jan;168(1):68-75
pubmed: 24276262
Value Health. 2019 Sep;22(9):1026-1032
pubmed: 31511179
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Dec;59(12):1623-1657
pubmed: 27885449
Vaccine. 2010 Nov 19;28 Suppl 6:G39-52
pubmed: 21075269
BMC Infect Dis. 2016 Aug 11;16(1):407
pubmed: 27514843
Public Health. 2022 May;206:57-62
pubmed: 35378455
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):106-9
pubmed: 26530279
PLoS One. 2012;7(2):e31239
pubmed: 22384005
Lancet. 2015 Dec 5;386(10010):2234-5
pubmed: 26361943
Hum Vaccin Immunother. 2022 Nov 30;18(5):2082205
pubmed: 35695748
Lancet. 2009 Sep 12;374(9693):893-902
pubmed: 19748398
JAMA. 2021 Dec 28;326(24):2521-2522
pubmed: 34962532
BMJ Open. 2018 Jun 30;8(6):e020619
pubmed: 29961011
MMWR Morb Mortal Wkly Rep. 2014 Nov 7;63(44):995-8
pubmed: 25375070
Clin Vaccine Immunol. 2014 Aug;21(8):1189-91
pubmed: 24920600
BMC Infect Dis. 2015 Oct 30;15:470
pubmed: 26515134
Eur J Pediatr. 2005 Oct;164(10):607-15
pubmed: 15965766
PLoS One. 2014 Dec 29;9(12):e111732
pubmed: 25545891
BMC Health Serv Res. 2018 May 2;18(1):318
pubmed: 29720156
Clin Microbiol Infect. 2015 Jan;21(1):35-42
pubmed: 25636925
J Laryngol Otol. 2013 Jan;127 Suppl 1:S30-4
pubmed: 23186827
Pneumonia (Nathan). 2015 Dec 1;6:101-114
pubmed: 31641584
Int J Pediatr Otorhinolaryngol. 2014 Oct;78(10):1599-604
pubmed: 25074345
Otolaryngol Clin North Am. 1991 Aug;24(4):757-61
pubmed: 1870869
Postgrad Med. 2015 May;127(4):386-90
pubmed: 25913598